Several years after approval of anti-vascular endothelial growth factor-targeted therapy for locally advanced and metastatic clear cell renal cell carcinoma, we discovered and/or validated new clinical, biochemical, pathological, pharmacokinetic, molecular and genetic markers predictive for response and/or prognostic in metastatic clear cell renal cell carcinoma patients treated with anti-vascular endothelial growth factor-receptor-tyrosine kinase inhibitors.

(BELG J MED ONCOL 2015;9(1):35–41)